Skip to main content
Toggle navigation
Search
Home
Icon Legend
Back
0
Like
Facebook
Tweet
Print
JoaQuin Bellmunt
Disclosure information not submitted.
Presentation(s):
PD10-02: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up Results From the JAVELIN Bladder 100 Trial
Friday, May 13, 2022
1:10 PM – 1:20 PM